| Dr Andrew M Cox, | |
|
40 Holland St, Somerville, MA 02144 | |
| (617) 629-6000 | |
| Not Available |
| Full Name | Dr Andrew M Cox |
|---|---|
| Gender | Male |
| Speciality | Pediatrics |
| Location | 40 Holland St, Somerville, Massachusetts |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1275929986 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | 273677 (Massachusetts) | Primary |
| Entity Name | Atrius Health Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1871639914 PECOS PAC ID: 4789588641 Enrollment ID: O20031121000582 |
News Archive
Project Ubuzima, an international not-for-profit group conducting clinical trials of microbicides, last week "assured the public" it will continue its trial of the microbicide Dapirivine in Rwanda, the New Times/AllAfrica.com reports.
The hot questions now are which of the nation's financial obligations would be paid and what would be left to default if the current negotiations fail to result in a deal. President Barack Obama would be forced to choose from among Social Security checks, salaries for members of the military and veterans, unemployment benefits and many other government programs.
Medical students and residents should receive much more thorough and realistic instruction about the economic forces affecting health care and their own clinical decisions so that they can better serve patients' well-being and the nation's economic welfare, says a commentary published today in a theme issue of the Journal of the American Medical Association, which focuses on improving medical education.
The European Union's highest court ruled Tuesday that scientists cannot patent stem cell techniques that use human embryos for research, a decision some scientists said could threaten major medical advances if it prevents biotech companies from turning a profit.
ETEX Corporation, an advanced biomaterials company, announced today that the FDA has granted 510(k) clearance of CarriGen® Porous Bone Substitute Material. CarriGen is available for immediate sale through ETEX's independent sales force. CarriGen builds upon the clinically proven benefit of ETEX nanocrystalline calcium phosphate technology by adding the advantage of increased porosity and pore size. CarriGen is the first highly porous bone graft substitute that sets hard upon implantation for a complete defect fill.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Andrew M Cox, 40 Holland St, Somerville, MA 02144-2705 Ph: (617) 629-6000 | Dr Andrew M Cox, 40 Holland St, Somerville, MA 02144 Ph: (617) 629-6000 |
News Archive
Project Ubuzima, an international not-for-profit group conducting clinical trials of microbicides, last week "assured the public" it will continue its trial of the microbicide Dapirivine in Rwanda, the New Times/AllAfrica.com reports.
The hot questions now are which of the nation's financial obligations would be paid and what would be left to default if the current negotiations fail to result in a deal. President Barack Obama would be forced to choose from among Social Security checks, salaries for members of the military and veterans, unemployment benefits and many other government programs.
Medical students and residents should receive much more thorough and realistic instruction about the economic forces affecting health care and their own clinical decisions so that they can better serve patients' well-being and the nation's economic welfare, says a commentary published today in a theme issue of the Journal of the American Medical Association, which focuses on improving medical education.
The European Union's highest court ruled Tuesday that scientists cannot patent stem cell techniques that use human embryos for research, a decision some scientists said could threaten major medical advances if it prevents biotech companies from turning a profit.
ETEX Corporation, an advanced biomaterials company, announced today that the FDA has granted 510(k) clearance of CarriGen® Porous Bone Substitute Material. CarriGen is available for immediate sale through ETEX's independent sales force. CarriGen builds upon the clinically proven benefit of ETEX nanocrystalline calcium phosphate technology by adding the advantage of increased porosity and pore size. CarriGen is the first highly porous bone graft substitute that sets hard upon implantation for a complete defect fill.
› Verified 1 days ago
Divya Vangala, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 33 Tower St, Somerville, MA 02143 Phone: 617-591-6300 | |
Natalie Diacovo, Pediatrics Medicare: Medicare Enrolled Practice Location: 236 Highland Ave, Somerville, MA 02143 Phone: 617-591-4440 | |
Dr. Marcia F Dworkind, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 40 Holland St, Somerville, MA 02144 Phone: 617-629-6300 Fax: 617-629-6090 | |
Dr. Dawn Marie Peters, MD Pediatrics Medicare: Accepting Medicare Assignments Practice Location: 40 Holland St, Somerville, MA 02144 Phone: 617-629-6300 Fax: 617-629-6090 | |
Benjamin A Kruskal, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 40 Holland St, Somerville, MA 02144 Phone: 617-629-6000 Fax: 617-629-6070 | |
Carole E Allen, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 40 Holland St, Somerville, MA 02144 Phone: 617-629-6000 Fax: 617-629-6070 |